2024-ASC-STUDENT
23.4.2024 09:03:33 CEST | Business Wire | Press release
On April 13, 2024, the 2024 ASC Student Supercomputer Challenge (ASC24) Finals drew to a close at Shanghai University after five days of intense competition. Peking University emerged as the undisputed overall champion, securing their place in ASC Student Supercomputer Challenge history.
After ASC24 registration opened on November 16, 2023, over 300 teams from universities participated in the intense preliminary contests. As a result, the absolute best 25 teams ascended to the finals hosted at Shanghai University from April 9 to 13, 2024. This marked a groundbreaking moment in ASC history, with the highest number of teams ever qualifying for onsite finals since the competition's inception in 2012.
During the finals, teams showcased their skills by designing and building cluster systems capped at a maximum power consumption of 3,000 W. They tackled a lineup of cutting-edge scientific and engineering applications, including HPL and HPCG benchmarks, Large Language Model (LLM), OpenCAEPoro, GoMars, and WannierTools. ASC24 featured again a group competition in which 25 teams, divided into 5 groups, explored the real-world application of ParaSeis. They simulated seismic wave propagation and refined algorithms through collaborative communication.
The competition reached its pinnacle when Peking University ultimately seized the coveted Champion title. Their performance not only impressed everyone but also demonstrated exceptional proficiency across various tasks such as GoMars, LLM, and WannierTools. This showed their expertise and unequaled mastery of comprehensive supercomputing systems, applications, and top-tier optimization skills.
The National Tsing Hua University team achieved significant results with the OpenCAEPoro task. They maximized the use of computing resources, executed large-scale parallel optimization of OpenCAEPoro while navigating power consumption constraints, and achieved the shortest run time, securing them the prestigious e Prize.
A collaborative effort led by Shanghai University, in partnership with the Southern University of Science and Technology, Qilu University of Technology, Southwest Petroleum University, and Hong Kong Polytechnic University, achieved remarkable optimization of ParaSeis. Their commendable teamwork and dedication were duly recognized with the prestigious Group Competition Award.
Additionally, the Zhejiang University team secured the Highest LINPACK Award, showcasing their exceptional computational prowess. Meanwhile, the outstanding performances of Shanxi University and Shanghai Jiao Tong University were properly honored with the coveted Application Innovation Award, recognizing their innovative contributions to the field.
Jack Dongarra, a distinguished member of the US National Academy of Engineering and recipient of the prestigious Turing Award, as well as a Distinguished Professor at both Oak Ridge National Laboratory and the University of Tennessee, and Chair of the ASC Advisory Committee, shared his insights during the closing ceremony of the ASC24 Finals: "ASC challenges and inspires the next generation of HPC scientists and engineers to deliver innovative solutions using the most cutting-edge technologies. The competition has been described as the world’s largest supercomputing hackathon, striving to foster the next generation of young talents to inspire exploration, innovation, and collaboration in Supercomputing and AI."
About ASC
The ASC Student Supercomputer Challenge stands as the globe's premier student supercomputer competition, with the generous support of experts and institutions spanning Asia, Europe, and America. ASC boasts a noble mission: to foster the exchange and cultivation of young supercomputing talent across borders, enhance supercomputing applications and research and development capabilities, propel the advancement of supercomputing technologies, and stimulate technical and industrial innovation. Since its inception in 2012, the ASC Student Supercomputer Challenge has grown every year, attracting over 10,000 undergraduates from every corner of the planet. To discover more about this impactful endeavor, visit the website.
http://www.asc-events.net/StudentChallenge/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423424820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom